{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma X"],"funding":["“100 Foreign Experts Plan of Hebei Province”, China"],"pagination":["e078782"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10946384"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(3)"],"pubmed_abstract":["<h4>Objectives</h4>This study aimed to investigate the impact of adjuvant chemotherapy (ACT) on survival outcomes in older women with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC).<h4>Design</h4>A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results database, which contains publicly available information from US cancer registries.<h4>Setting and participants</h4>The study included 45 762 older patients with BC aged over 65 years diagnosed between 2010 and 2015.<h4>Methods</h4>Patients were divided into two groups based on age: 65-79 years and ≥80 years. Propensity score matching (PSM) was employed to balance clinicopathological characteristics between patients who received ACT and those who did not. Data analysis used the χ<sup>2</sup> test and Kaplan-Meier method, with a subgroup analysis conducted to identify potential beneficiaries of ACT.<h4>Outcome measures</h4>Overall survival (OS) and cancer-specific survival (CSS).<h4>Results</h4>Due to clinicopathological characteristic imbalances between patients with BC aged 65-79 years and those aged ≥80 years, PSM was used to categorise the population into two groups for analysis: the 65-79 years age group (n=38 128) and the ≥80 years age group (n=7634). Among patients aged 65-79 years, Kaplan-Meier analysis post-PSM indicated that ACT was effective in improving OS (p<0.05, HR=0.80, 95% CI 0.73 to 0.88), particularly in those with advanced disease stages, but did not show a significant benefit in CSS (p=0.09, HR=1.13, 95% CI 0.98 to 1.31). Conversely, for patients aged ≥80 years, ACT did not demonstrate any improvement in OS (p=0.79, HR=1.04, 95% CI 0.79 to 1.36) or CSS (p=0.09, HR=1.46, 95% CI 0.69 to 2.26) after matching. Subgroup analysis also revealed no positive impact on OS and CSS.<h4>Conclusions</h4>Patients with HR+/HER2- BC ≥80 years of age may be considered exempt from ACT because no benefits were found in terms of OS and CSS."],"journal":["BMJ open"],"pubmed_title":["Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database."],"pmcid":["PMC10946384"],"funding_grant_id":["2022001"],"pubmed_authors":["Chen N","Liu Y","Cao M","Zhang X","Ma X","Wu S","Du K","Yang C"],"additional_accession":[]},"is_claimable":false,"name":"Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.","description":"<h4>Objectives</h4>This study aimed to investigate the impact of adjuvant chemotherapy (ACT) on survival outcomes in older women with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC).<h4>Design</h4>A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results database, which contains publicly available information from US cancer registries.<h4>Setting and participants</h4>The study included 45 762 older patients with BC aged over 65 years diagnosed between 2010 and 2015.<h4>Methods</h4>Patients were divided into two groups based on age: 65-79 years and ≥80 years. Propensity score matching (PSM) was employed to balance clinicopathological characteristics between patients who received ACT and those who did not. Data analysis used the χ<sup>2</sup> test and Kaplan-Meier method, with a subgroup analysis conducted to identify potential beneficiaries of ACT.<h4>Outcome measures</h4>Overall survival (OS) and cancer-specific survival (CSS).<h4>Results</h4>Due to clinicopathological characteristic imbalances between patients with BC aged 65-79 years and those aged ≥80 years, PSM was used to categorise the population into two groups for analysis: the 65-79 years age group (n=38 128) and the ≥80 years age group (n=7634). Among patients aged 65-79 years, Kaplan-Meier analysis post-PSM indicated that ACT was effective in improving OS (p<0.05, HR=0.80, 95% CI 0.73 to 0.88), particularly in those with advanced disease stages, but did not show a significant benefit in CSS (p=0.09, HR=1.13, 95% CI 0.98 to 1.31). Conversely, for patients aged ≥80 years, ACT did not demonstrate any improvement in OS (p=0.79, HR=1.04, 95% CI 0.79 to 1.36) or CSS (p=0.09, HR=1.46, 95% CI 0.69 to 2.26) after matching. Subgroup analysis also revealed no positive impact on OS and CSS.<h4>Conclusions</h4>Patients with HR+/HER2- BC ≥80 years of age may be considered exempt from ACT because no benefits were found in terms of OS and CSS.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-20T02:48:36.201Z","creation":"2025-02-19T03:09:00.582Z"},"accession":"S-EPMC10946384","cross_references":{"pubmed":["38490656"],"doi":["10.1136/bmjopen-2023-078782"]}}